| For: | Al-Busafi SA, Alwassief A, Madian A, Atalla H, Alboraie M, Elbahrawy A, Eslam M. Exploring the interplay between metabolic dysfunction-associated fatty liver disease and gut dysbiosis: Pathophysiology, clinical implications, and emerging therapies. World J Hepatol 2025; 17(8): 108730 [PMID: 40901606 DOI: 10.4254/wjh.v17.i8.108730] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v17/i8/108730.htm |
| Number | Citing Articles |
| 1 |
Jhommara Bautista, Andrés López-Cortés. The hallmarks of host-microbiome decoupling. Frontiers in Microbiology 2026; 17 doi: 10.3389/fmicb.2026.1801100
|
| 2 |
Poonam Sahu, Trilochan Satapathy. The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets. Probiotics and Antimicrobial Proteins 2026; doi: 10.1007/s12602-026-11050-6
|
| 3 |
春漫 薛. Mechanisms, Epidemiology and Diagnostic Strategies of Metabolic Dysfunction-Associated Fatty Liver Disease. Journal of Clinical Personalized Medicine 2026; 5(02) doi: 10.12677/jcpm.2026.52138
|
| 4 |
Said A. Al-Busafi, Mohammed Eslam. The AMAGE guidelines: Metabolic dysfunction-associated fatty liver disease through a regional lens. Annals of Hepatology 2026; 31(1) doi: 10.1016/j.aohep.2026.102205
|
| 5 |
Wu Bao, Gaopeng Li, Yuan Ding, Yuhao Wang. Harnessing the gut microbiome for MASLD management: opportunities and challenges. Science Bulletin 2026; doi: 10.1016/j.scib.2026.05.017
|